The results indicate a prolonged duration of response, significant B-cell depletion, and a well-tolerated safety profile when AlloNK is combined with rituximab. Additionally, the company will ...

Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK® + rituximab for the treatment of B-cell driven diseases in a community ...

Using a blood test developed by Dr Fritz Bach, Dr Robert Good determined that the patient, a baby with a severe immune deficiency ... Rituximab, a monoclonal antibody targeting CD-20 positive B ...

as a deeper depletion of autoreactive MBCs could be established by adding B-cell-depleting therapy after the initiation of BLM. References: [1]Arends EJ et al. Long-term effects of combined B cell ...

An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according ...

Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely focused on CAR-Ts and bispecifics, the German drugmaker has paid Cue ...

Long-term results from a randomized trial confirmed that early rituximab monotherapy for advanced-stage, asymptomatic, low ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Variability in rituximab pharmacokinetics has been well documented in B-cell malignancies and RA. Early studies in NHL employing the same treatment regimen found remarkable variability in serum ...